AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39340233 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine powder air-abrasive debridement
Number of subjects: 30
Study 39340233 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic instrumentation
Number of subjects: 30
Study 39340493 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 1038
Study 39340688 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin (CMS) administered at a dosage of 6.75 MUI q12 after a 9 MIU loading dose.
Number of subjects: 20
Study 39340691 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib plus standard PD treatment (levodopa/carbidopa)
Number of subjects: 60
Study 39340691 — intervention group
Group type: COMPARATOR
Intervention: Standard PD treatment (levodopa/carbidopa)
Number of subjects: 60
Study 39340711 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone (10 mg and 20 mg)
Number of subjects: 504
Study 39340758 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg orally for 26 weeks
Number of subjects: 31
Study 39340758 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 31
Study 39340758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 39341033 — intervention group
Group type: EXPERIMENTAL
Intervention: multicomponent exercise emphasizing progressive resistance training
Number of subjects: 570
Study 39341033 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 570
Study 39341091 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC prediction model using linear support vector machine (SVM)
Number of subjects: 131
Study 39341091 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics-based nomograms
Number of subjects: 131
Study 39341091 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression analysis of NAC responders
Number of subjects: 131
Study 39341368 — intervention group
Group type: EXPERIMENTAL
Intervention: Etranacogene dezaparvovec gene therapy
Number of subjects: 29
Study 39341368 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous FIX infusion
Number of subjects: 29
Study 39341368 — intervention group
Group type: EXPERIMENTAL
Intervention: No or a single FIX infusion
Number of subjects: 29
Study 39341368 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative management
Number of subjects: 29
Study 39341405 — intervention group
Group type: EXPERIMENTAL
Intervention: N protein-based vaccine (50 µg)
Number of subjects: 5229
Study 39341405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5229
Study 39341436 — intervention group
Group type: EXPERIMENTAL
Intervention: OmniaSecure defibrillation lead
Number of subjects: 0
Study 39341482 — intervention group
Group type: EXPERIMENTAL
Intervention: Penn Medicine Healthy Heart intervention
Number of subjects: 2420
Study 39341482 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2420
Study 39341700 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA analysis using FoundationOne Liquid CDx and FoundationOneMonitor assays
Number of subjects: 109
Study 39341700 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ctDNA changes at day 15/22
Number of subjects: 109
Study 39341942 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleneonatal resuscitation
Number of subjects: 51
Study 39341942 — intervention group
Group type: COMPARATOR
Intervention: Routine resuscitation
Number of subjects: 51
Study 39342143 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MEANING)
Number of subjects: 55
Study 39342143 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 55
Study 39342143 — intervention group
Group type: COMPARATOR
Intervention: Both conditions (Mindfulness and Usual care)
Number of subjects: 55
Study 39342159 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphagia at hospital admission
Number of subjects: 2054
Study 39342159 — intervention group
Group type: COMPARATOR
Intervention: Older age
Number of subjects: 2054
Study 39342159 — intervention group
Group type: COMPARATOR
Intervention: NIHSS score
Number of subjects: 2054
Study 39342159 — intervention group
Group type: COMPARATOR
Intervention: Charlson Comorbidity Index (CCI) score
Number of subjects: 2054
Study 39342159 — intervention group
Group type: COMPARATOR
Intervention: Hypertension
Number of subjects: 2054
Study 39342159 — intervention group
Group type: COMPARATOR
Intervention: Atrial fibrillation
Number of subjects: 2054
Study 39342159 — intervention group
Group type: COMPARATOR
Intervention: Diabetes
Number of subjects: 2054
Study 39342159 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking status
Number of subjects: 2054
Study 39342159 — intervention group
Group type: COMPARATOR
Intervention: Myocardial infarction
Number of subjects: 2054
Study 39342159 — intervention group
Group type: COMPARATOR
Intervention: Heart failure
Number of subjects: 2054
Study 39342159 — intervention group
Group type: COMPARATOR
Intervention: Peripheral arterial disease
Number of subjects: 2054
Study 39342159 — intervention group
Group type: COMPARATOR
Intervention: Severe chronic liver disease
Number of subjects: 2054
Study 39342159 — intervention group
Group type: COMPARATOR
Intervention: Kidney disease
Number of subjects: 2054
Study 39342159 — intervention group
Group type: COMPARATOR
Intervention: Overall CCI
Number of subjects: 2054
Study 39342204 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually-prescribed exercises
Number of subjects: 0
Study 39342204 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit training resources
Number of subjects: 0
Study 39342204 — intervention group
Group type: COMPARATOR
Intervention: Standardized exercises
Number of subjects: 0
Study 39342204 — intervention group
Group type: COMPARATOR
Intervention: Generic behavior prompts
Number of subjects: 0
Study 39342220 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant abdominal massage class by a certified instructor
Number of subjects: 160
Study 39342220 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 160
Study 39342272 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM)
Number of subjects: 300
Study 39342272 — intervention group
Group type: COMPARATOR
Intervention: Community Early Behavioral Intervention (EBI)
Number of subjects: 300
Study 39342334 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal guided bone regeneration (GBR) utilizing a resorbable collagen membrane and a split-thickness flap design
Number of subjects: 8
Study 39342346 — intervention group
Group type: EXPERIMENTAL
Intervention: bilateral erector spinae blockade
Number of subjects: 70
Study 39342346 — intervention group
Group type: COMPARATOR
Intervention: left sided serratus anterior plane block plus subcostal TAP blocks
Number of subjects: 70
Study 39342378 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (perspective-taking workshop before dialogue)
Number of subjects: 163
Study 39342378 — intervention group
Group type: COMPARATOR
Intervention: Partial intervention (perspective-taking workshop after dialogue)
Number of subjects: 163
Study 39342378 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention
Number of subjects: 163
Study 39342378 — intervention group
Group type: COMPARATOR
Intervention: Partial intervention
Number of subjects: 163
Study 39342378 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 163
Study 39342464 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Cost Campaign Advertisements
Number of subjects: 0
Study 39342464 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39342463 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 727965 (dinaciclib) 50 mg/m
Number of subjects: 72
Study 39342512 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 6001
Study 39342512 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone (LVEF <50%)
Number of subjects: 6001
Study 39342512 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone (LVEF ≥50% to <60%)
Number of subjects: 6001
Study 39342512 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone (LVEF ≥60%)
Number of subjects: 6001
Study 39342512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6001
Study 39342513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-field portable magnetic resonance imaging (ULF-pMRI)
Number of subjects: 50
Study 39342513 — intervention group
Group type: COMPARATOR
Intervention: Head computed tomography (CT)
Number of subjects: 50
Study 39342655 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 6001
Study 39342655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6001
Study 39342881 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Glucose Tolerant (NGT)
Number of subjects: 110
Study 39342881 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerant (IGT)
Number of subjects: 110
Study 39342881 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic (DM)
Number of subjects: 110
Study 39342881 — intervention group
Group type: EXPERIMENTAL
Intervention: Longstanding-DM
Number of subjects: 110
Study 39342881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose levels
Number of subjects: 110
Study 39342881 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide levels
Number of subjects: 110
Study 39342881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 110
Study 39342881 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide
Number of subjects: 110
Study 39342905 — intervention group
Group type: EXPERIMENTAL
Intervention: Mom Supports Mom (MSM) intervention
Number of subjects: 167
Study 39342905 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 167
Study 39343051 — intervention group
Group type: COMPARATOR
Intervention: Single endoscopic balloon dilation (EBD)
Number of subjects: 21
Study 39343051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with 3 balloon dilations 3 weeks apart and/or needle-knife stricturotomy (NKSt)
Number of subjects: 21
Study 39343051 — intervention group
Group type: EXPERIMENTAL
Intervention: NKSt
Number of subjects: 21
Study 39343051 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent intensified drug treatment
Number of subjects: 21
Study 39343120 — intervention group
Group type: EXPERIMENTAL
Intervention: AVEIR DR (Abbott) leadless pacemaker system
Number of subjects: 0
Study 39343122 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR training (86% of respondents)
Number of subjects: 2395
Study 39343122 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR training in the last year (25.1%)
Number of subjects: 2395
Study 39343122 — intervention group
Group type: EXPERIMENTAL
Intervention: Witnessing CPR (26.9%)
Number of subjects: 2395
Study 39343122 — intervention group
Group type: EXPERIMENTAL
Intervention: General CPR training mandates
Number of subjects: 2395
Study 39343173 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (type 2 immune blockade)
Number of subjects: 71
Study 39343244 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nirmatrelvir/ritonavir (NMV/r) 300/100 mg BID
Number of subjects: 991
Study 39343244 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sotrovimab (SOT)
Number of subjects: 991
Study 39343244 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular tixagevimab/cilgavimab (TGM/CGM)
Number of subjects: 991
Study 39343244 — intervention group
Group type: COMPARATOR
Intervention: SOT
Number of subjects: 991
Study 39343244 — intervention group
Group type: EXPERIMENTAL
Intervention: NMV/r
Number of subjects: 991
Study 39343247 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 (2-Dose) administered on day 0 and day 21
Number of subjects: 288
Study 39343247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 39343309 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of psilocybin
Number of subjects: 15
Study 39343313 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based interpersonal psychotherapy (IPT) for 10 weeks with weekly therapist guidance
Number of subjects: 113
Study 39343313 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 113
Study 39343385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for 24 weeks
Number of subjects: 0
Study 39343385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for 52 weeks
Number of subjects: 0
Study 39343385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39343425 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks
Number of subjects: 76
Study 39343425 — intervention group
Group type: COMPARATOR
Intervention: Standard 6-month regimen
Number of subjects: 76
Study 39343453 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour reduction intervention (1 hour/day reduction)
Number of subjects: 64
Study 39343453 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued as usual)
Number of subjects: 64
Study 39343453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 39343453 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole study group
Number of subjects: 64
Study 39343511 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab (N+I)
Number of subjects: 66
Study 39343511 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab (N)
Number of subjects: 66
Study 39343510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (1 mg/kg intravenously every 6 weeks) plus Nivolumab (240 mg intravenously every 2 weeks)
Number of subjects: 16
Study 39343510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus Nivolumab
Number of subjects: 16
Study 39343865 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral pre-exposure prophylaxis pills
Number of subjects: 25
Study 39343865 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly dapivirine vaginal ring
Number of subjects: 25
Study 39343891 — intervention group
Group type: EXPERIMENTAL
Intervention: Various assessments during maternal visits including medical history, diet, physical activity, sleep, perceived stress, and socioeconomic/sociocultural information.
Number of subjects: 0
Study 39343891 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard laboratory tests during maternal visits including glycemic measures, lipids, and renal function.
Number of subjects: 0
Study 39343891 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive research visits for offspring at various ages (6-12 weeks, 4 months, 6 months, 18 months, 2 years, 3 years, 4-5 years, 6-9 years, 10-13 years, 14-17 years) including medical history, anthropometry, developmental assessment, and biochemical tests.
Number of subjects: 0
Study 39343891 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic/epigenetic testing and ultrasound elastography during major visits.
Number of subjects: 0
Study 39343892 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (TM) follow-up intervention
Number of subjects: 26
Study 39343942 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (weekly, supervised, 30-45 min sessions, encouraged to accumulate more than 5000 steps per day)
Number of subjects: 109
Study 39343942 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (control group)
Number of subjects: 109
Study 39343942 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 109
Study 39343969 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic control training
Number of subjects: 427
Study 39343969 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint position sense
Number of subjects: 427
Study 39343969 — intervention group
Group type: COMPARATOR
Intervention: Comparison between DCD and TD groups
Number of subjects: 427
Study 39344118 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD men
Number of subjects: 827
Study 39344118 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD patients
Number of subjects: 827
Study 39344118 — intervention group
Group type: COMPARATOR
Intervention: Non-CVD population
Number of subjects: 827
Study 39344233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic system dysfunction
Number of subjects: 0
Study 39344233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic reductions in the extended connectivity between the thalamic complex and the temporal limbic system
Number of subjects: 0
Study 39344233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic changes in the cerebellum
Number of subjects: 0
Study 39344281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaplacide 200 mg plus LUM-SDF 960 mg (run-in part)
Number of subjects: 446
Study 39344281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaplacide-LUM-SDF regimens (Part A)
Number of subjects: 446
Study 39344281 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (Part A)
Number of subjects: 446
Study 39344281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaplacide-LUM-SDF regimens (Part B)
Number of subjects: 446
Study 39344281 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (Part B)
Number of subjects: 446
Study 39344366 — intervention group
Group type: EXPERIMENTAL
Intervention: DOAC
Number of subjects: 169
Study 39344366 — intervention group
Group type: COMPARATOR
Intervention: VKA
Number of subjects: 169
Study 39344366 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant switching
Number of subjects: 169
Study 39344509 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk plaques present
Number of subjects: 484
Study 39344509 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcified plaque burden
Number of subjects: 484
Study 39344509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-attenuation plaque burden
Number of subjects: 484
Study 39344509 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score
Number of subjects: 484
Study 39344509 — intervention group
Group type: EXPERIMENTAL
Intervention: MACE
Number of subjects: 484
Study 39344509 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 484
Study 39344637 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine treatment (exact dosage and duration not specified)
Number of subjects: 0
Study 39344637 — intervention group
Group type: COMPARATOR
Intervention: Control group (exact treatment not specified)
Number of subjects: 0
Study 39344652 — intervention group
Group type: EXPERIMENTAL
Intervention: HF with mildly reduced EF
Number of subjects: 16562
Study 39344652 — intervention group
Group type: EXPERIMENTAL
Intervention: HF with reduced EF
Number of subjects: 16562
Study 39344652 — intervention group
Group type: COMPARATOR
Intervention: HF with preserved EF
Number of subjects: 16562
Study 39345001 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Self Advocacy Scale (PSAS)
Number of subjects: 111
Study 39345094 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib, lenalidomide, and dexamethasone
Number of subjects: 0
Study 39345094 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39345118 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI therapy for 12 weeks
Number of subjects: 26
Study 39345118 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI therapy
Number of subjects: 26
Study 39345688 — intervention group
Group type: EXPERIMENTAL
Intervention: Oviderm® or Canoderm® (intervention creams)
Number of subjects: 78
Study 39345688 — intervention group
Group type: COMPARATOR
Intervention: Decubal® lipid cream (comparator)
Number of subjects: 78
Study 39345782 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent vegans
Number of subjects: 0
Study 39345782 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherent vegans
Number of subjects: 0
Study 39345782 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent omnivores
Number of subjects: 0
Study 39345782 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherent omnivores
Number of subjects: 0
Study 39345833 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral doses of 14,000 IU vitamin D
Number of subjects: 0
Study 39345833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39345833 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 39345834 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PBMT associated with MCE
Number of subjects: 148
Study 39345834 — intervention group
Group type: COMPARATOR
Intervention: Placebo PBMT associated with MCE
Number of subjects: 148
Study 39346010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel preparation through a mid-gut tube
Number of subjects: 95
Study 39346010 — intervention group
Group type: COMPARATOR
Intervention: Bowel preparation by oral administration
Number of subjects: 95
Study 39346117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab plus carboplatin-paclitaxel
Number of subjects: 487
Study 39346117 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin-paclitaxel
Number of subjects: 487
Study 39346497 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week tele-exercise program
Number of subjects: 3
Study 39346497 — intervention group
Group type: COMPARATOR
Intervention: No tele-exercise (Control Group B)
Number of subjects: 3
Study 39346497 — intervention group
Group type: COMPARATOR
Intervention: No tele-exercise (Control Group C)
Number of subjects: 3
Study 39346668 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood culture diagnostic stewardship strategies
Number of subjects: 14
Study 39346668 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-performing site strategies
Number of subjects: 14
Study 39346668 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic stewardship program
Number of subjects: 14
Study 39347584 — intervention group
Group type: EXPERIMENTAL
Intervention: Liso-cel (autologous, CD19-directed, 4-1BB CAR T-cell product)
Number of subjects: 82
Study 39347697 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten treatment for 26 weeks starting at 2.5 mg and potentially titrated up to 5 mg at week 14.
Number of subjects: 30